Publication Name	World Journal of Immunology
Manuscript ID	21006
Country	Bulgaria

Received	2015-06-29 08:44
Peer-Review Started	2015-06-29 15:44
To Make the First Decision	2015-11-06 11:08
Return for Revision	2015-11-10 08:32
Revised	2015-11-24 15:45
Second Decision	2015-12-07 09:28
Accepted by Journal Editor-in-Chief	2015-12-07 14:21
Accepted by Company Editor-in-Chief	2015-12-14 17:46
Articles in Press	2015-12-14 17:46
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2016-03-24 17:57
Publish the Manuscript Online	2016-03-28 08:57

ISSN	2219-2824 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Immunology
Manuscript Type	Review
Article Title	Maillard reaction and immunogenicity of protein therapeutics
Manuscript Source	Invited Manuscript
All Author List	Rositsa Tsekovska, Angelina Sredovska-Bozhinov, Toshimitsu Niwa, Ivan Ivanov and Roumyana Mironova
Funding Agency and Grant Number
Corresponding Author	Roumyana Mironova, Professor, Institute of Molecular Biology Roumen Tsanev, Bulgarian Academy of Sciences, Acad. G. Bonchev str., bl. 21, 1113 Sofia, Bulgaria. rumym@bio21.bas.bg
Key Words	Maillard reaction; Glycation; Advanced glycation end products; Protein therapeutics; Inter­feron-b; Immunogenicity
Core Tip	The Maillard reaction occurs spontaneously in host cells and causes covalent modifications, proteolysis and crosslinking of therapeutic proteins. These are gross structural changes, which upon administration may provoke in patients classical type innate and adaptive immune responses. The consequences of the Maillard reaction, however, reach far beyond. Specific and non-specific cellular receptors for the advanced products of the Maillard reaction may further enhance the immune response and elicit inflammation. All together the Maillard reaction actions are expected to result in drug neutralization and side effects in treated patients such as inflammatory and hypersensitivity reactions.
Publish Date	2016-03-28 08:57
Citation	Tsekovska R, Sredovska-Bozhinov A, Niwa T, Ivanov I, Mironova R. Maillard reaction and immunogenicity of protein therapeutics. World J Immunol 2016; 6(1): 19-38
URL	http://www.wjgnet.com/2219-2824/full/v6/i1/19.htm
DOI	http://dx.doi.org/10.5411/wji.v6.i1.19

Full Article (PDF)	WJI-6-19.pdf
Full Article (Word)	WJI-6-19.doc
Manuscript File	21006-Review.docx
Answering Reviewers	21006-Answering reviewers.pdf
Audio Core Tip	21006-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	21006-Conflict-of-interest statement.pdf
Copyright License Agreement	21006-Copyright assignment.pdf
Peer-review Report	21006-Peer-review(s).pdf
Journal Editor-in-Chief Review Report	21006-Journal editor-in-chief review report.pdf
Scientific Misconduct Check	21006-Scientific misconduct check.pdf
Scientific Editor Work List	21006-Scientific editor work list.pdf